<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56096">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02375867</url>
  </required_header>
  <id_info>
    <org_study_id>NLI-FHF-S-PED</org_study_id>
    <nct_id>NCT02375867</nct_id>
  </id_info>
  <brief_title>Steroids in Fulminant Hepatic Failure in the Pediatric Age Group</brief_title>
  <official_title>Safety and Efficacy of Steroids in the Management of Fulminant Hepatic Failure in the Pediatric Age Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Liver Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quesna Central Hospital, Ministry Of Health, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Liver Institute, Egypt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fulminant hepatic failure (FHF) in children is a potentially devastating disease. The
      mortality rate may reach 80-90% in the absence of liver transplantation. Liver injury is
      considered to be mainly immune mediated with augmentation of cytolytic pathways of infected
      hepatocytes. For that, it is suggested that corticosteroids modulate the activity of the
      disease by suppressing the immune system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fulminant hepatic failure (FHF) in children is a potentially devastating disease. The
      mortality rate may reach 80-90% in the absence of liver transplantation. FHF is the clinical
      manifestation of liver cell death of a critical degree with insufficient hepatocellular
      regeneration and characterized by coagulopathy with or without hepatic encephalopathy.

      Liver injury is considered to be mainly immune mediated with augmentation of cytolytic
      pathways of infected hepatocytes. For that, it was suggested that corticosteroids modulate
      the activity of the disease by suppressing the immune system.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>participants will be followed for the duration of hospital stay and allover the follow up period after hospital discharge, an expected average of 2 months.</time_frame>
    <description>Clinical and laboratory monitoring of patients for occurrence of side effects such as anaphylaxis, angioedema, cardiac arrest, cardiac arrhythmias, circulatory collapse, congestive heart failure, fat embolism, pulmonary edema, thromboembolism, pancreatitis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in survival (without transplant).</measure>
    <time_frame>within 30 days of disease onset</time_frame>
    <description>To evaluate the efficacy of steroids in improving the patient survival without the need for liver transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of prothrombin time</measure>
    <time_frame>72 hour of start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of encephalopathy by one grade or more.</measure>
    <time_frame>72 hour of start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of consciousness recovery time (CRT) among survivors</measure>
    <time_frame>Within 30 days of disease onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolongation of time to death among non-survivors.</measure>
    <time_frame>Within 30 days of disease onset</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Relation of the causative agent with the progression of the disease and response to the therapy.</measure>
    <time_frame>Participants will be followed for the duration of hospital stay and allover the follow up period after hospital discharge, an expected average of 2 months.</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Fulminant Hepatic Failure</condition>
  <arm_group>
    <arm_group_label>prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group includes patients with FHF without encephalopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group includes patients with FHF with encephalopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retrospective non-intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>A retrospective data analysis of FHF patients without any of the proposed intervention as controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
    <description>Oral administration of 1 mg/Kg/day</description>
    <arm_group_label>prednisolone</arm_group_label>
    <other_name>Hostacortin-H</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>Intravenous injection of 0.8 mg/kg/day</description>
    <arm_group_label>methylprednisolone</arm_group_label>
    <other_name>Solumedrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The patient is diagnosed to have FHF, if he fulfilled all the following criteria:

          1. Evidence of liver dysfunction within 8 weeks of onset of symptoms (neonates may have
             only deranged liver functions without overt symptoms).

          2. Uncorrectable coagulopathy (6-8 hours after administration of one dose of parenteral
             vitamin K) with International Normalized Ratio (INR) &gt;1.5 in patients with hepatic
             encephalopathy, or INR&gt; 2.0 in patients without encephalopathy.

          3. No evidence of chronic liver disease.

        Exclusion Criteria:

          1. Presence of absolute contra-indications to steroid therapy (as presence of an active
             gastrointestinal bleeding, renal failure, acute pancreatitis, active tuberculosis,
             uncontrolled diabetes and psychosis).

          2. Presence of absolute contra-indications to growth hormone therapy (as active
             malignancy, benign intracranial hypertension, proliferative or pre-proliferative
             diabetic retinopathy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanaa El-Araby, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Hepatology Department, National Liver Institute, Egypt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mostafa M Sira, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Pediatric Hepatology Department, National Liver Institute, Egypt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haydi M Zakaria, M.Sc.</last_name>
    <role>Study Chair</role>
    <affiliation>Quesna Central Hospital, Ministry Of Health, Egypt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tahany A Salem, M.Sc.</last_name>
    <role>Study Chair</role>
    <affiliation>Pediatric Hepatology Department, National Liver Institute, Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanaa A El-Araby, M.D.</last_name>
    <phone>+2-048-222-2740</phone>
    <email>helaraby@liver-eg.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haidy M Zakaria, M.Sc</last_name>
    <phone>+2-0100-5768-306</phone>
    <email>drhaydi2000@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Liver Institute</name>
      <address>
        <city>Menoufiya</city>
        <zip>32511</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanaa A El-Araby, M.D.</last_name>
      <phone>+2-048-222-2740</phone>
      <email>helaraby@liver-eg.org</email>
    </contact>
    <contact_backup>
      <last_name>Haidy M Zakaria, M.Sc.</last_name>
      <phone>+20100-5768-306</phone>
      <email>drhaydi2000@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hanaa A El-Araby, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mostafa M Sira, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Haidy M Zakaria, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tahany A Salem, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmad M Sira, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Doaa Y Elbadry, M.B; B.Ch.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed A Ali, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rawan M Salama, M.B; B.Ch.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Menan E Salem, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shaimaa S Goda, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara M Eltaras, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Basma M Abd-Alaaty, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fatma O Khalil, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sahar S Abou-Zeinah, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Cochran JB, Losek JD. Acute liver failure in children. Pediatr Emerg Care. 2007 Feb;23(2):129-35. Review.</citation>
    <PMID>17351416</PMID>
  </reference>
  <reference>
    <citation>Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet. 2010 Jul 17;376(9736):190-201. doi: 10.1016/S0140-6736(10)60274-7. Review.</citation>
    <PMID>20638564</PMID>
  </reference>
  <reference>
    <citation>Fujiwara K, Kojima H, Yasui S, Okitsu K, Yonemitsu Y, Omata M, Yokosuka O. Hepatitis A viral load in relation to severity of the infection. J Med Virol. 2011 Feb;83(2):201-7. doi: 10.1002/jmv.21958.</citation>
    <PMID>21181913</PMID>
  </reference>
  <reference>
    <citation>Fujiwara K, Yasui S, Yonemitsu Y, Fukai K, Arai M, Imazeki F, Suzuki A, Suzuki H, Sadahiro T, Oda S, Yokosuka O. Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B. J Gastroenterol. 2008;43(9):711-9. doi: 10.1007/s00535-008-2222-5. Epub 2008 Sep 20.</citation>
    <PMID>18807133</PMID>
  </reference>
  <reference>
    <citation>Lahuna O, Rastegar M, Maiter D, Thissen JP, Lemaigre FP, Rousseau GG. Involvement of STAT5 (signal transducer and activator of transcription 5) and HNF-4 (hepatocyte nuclear factor 4) in the transcriptional control of the hnf6 gene by growth hormone. Mol Endocrinol. 2000 Feb;14(2):285-94.</citation>
    <PMID>10674400</PMID>
  </reference>
  <reference>
    <citation>Seshadri R, Feldman BM, Ilowite N, Cawkwell G, Pachman LM. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum. 2008 Jul 15;59(7):989-95. doi: 10.1002/art.23829.</citation>
    <PMID>18576304</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>February 14, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Liver Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Mostafa M. Sira</investigator_full_name>
    <investigator_title>Associate Professor of Pediatric Hepatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
